And we’ll just have to wait and see what they are. And we’ll weigh our options at the time. But the beauty is, that’s why I am very confident that we’re never going to have to do anything diluted for shareholders. And the reason is, because we’re building all this underlying value in our company and what’s nice, the under — unlike a pure biotech company that’s spending a fortune developing a cancer drug that knows that they’re going to have to raise more money. If they don’t do a deal with major pharma, people are going to be scared to invest in their company knowing that there’s a race coming. In our situation we’re building underlying yes, we do have the cancer drug that we’re developing, but that’s at minimal cost. And it’s, it’s a rounding error in the scheme of things of everything else we’re doing.
But we have these two subsidiaries, where the revenues are about to take off. And therefore, and then the earnings will follow right behind. And when you have subsidiaries, where the revenues and earnings are taking off, and there’s a perspective that the future is bright. And when you start seeing the demand, I mean, our lozenges, we have demand for when we build our capacity out a year from now. And when you have that type of visibility, investors will pay big for that because you’re not risking something like a biotech drug that that will fail. You’re talking about a business model, where you can visibly see the revenues and earnings growing, and you’re getting a nice return on your investment. So my point simply be, I can’t tell you if we’re going to do IPOs, or spin outs, or I shouldn’t even comment on that kind of stuff.
But what I can tell you is that those will be options that will be available to us whether we’re in a bull market or a bear market, because we will have businesses that are generating revenues and earnings and have visibility for significantly greater demand. So I hope that answers your question is spot on. It’s a spot on question is absolutely the way investors should be thinking about a company. And we’ll say. And I believe we have time Nick. Thank you so much for the question. And as always, really appreciate your support. And, Nick, I think we have time for one more question. Thank you. That’ll be from Paul Barker [ph] PLA Associates. Please go ahead.
Unidentified Analyst: Hey, Ted, thanks for taking the call. I’m still a little unclear on the accounts receivable issue. And you certainly sound like you have a lot of potential with a lot of things. And I hope that works out. But we also have to look on how execution happens. And one, I don’t know where you got the number $33 million for your accounts receivable when your financials is $38 million at September 30.
Ted Karkus : I apologize. I misquoted, if it’s $38 million at the end of the quarter. Let me look at that.
Unidentified Analyst: And [multiple speakers]
Ted Karkus : Let me cut to the chase. And that’s really funny, because I thought we were out of time. I said, Let me squeeze in one more question. I hope it’s going to be a good question. I’ve spent the enormous amount of time on our accounts receivable already. I’m sorry, if this is the last question. I’ve given you the answer. These are high quality insurance companies. I can’t guarantee we’re going to collect on all the accounts receivable. We’ll make that decision at year end. But we have money coming in every week from our accounts receivable. So it’s not like it’s not a real accounts receivable. And the amount of money coming in is greater than our negative cash flow.
Unidentified Analyst: What are you — what is these [multiple speakers]?
Ted Karkus : Well, let me — let me put it this way. I’m sorry, this is the last question. I don’t want to cut you off. But what is your question that you’re looking for an answer that I didn’t already go over ad naseum?
Unidentified Analyst: Well to me, it looks like you’ve got at least half the accounts receivables that are over a year old, or certainly nine months?
Ted Karkus : And so, we did. Okay, so let me explain. I’ve explained in some prior calls. We did a significant amount of COVID testing the first half of the year. So we collected on a significant amount of accounts receivable from last year. And it was replaced by new accounts receivable from this year. So it’s not the same accounts receivable. So do we still have some accounts receivable from last year? Yes. Are we collecting on it? Yes. In fact, I’m not going to go into details. We have one major insurance company that owes us a big block of money for last year and we’ve been negotiating with them. And they agree that they owe us the money, but they want to go specimen by specimen now and drag it out instead of come to a settlement. But they’re going to pay us off substantially all of what they owe us. But it’s coming in dribs and drabs. I’m frustrated by it. Obviously, it sounds like you’re. So –but I don’t know what else do you want me to tell you?
Unidentified Analyst: I mean, I just have —
Ted Karkus : Frustrated by accounts receivable and it’s flowing in. And whatever rate it flows in it flows in. I’m building what I believe are multi $100 million businesses. I believe that we’re going to collect substantially on our accounts receivable. I don’t know what the exact numbers, but money is coming in every week. That’s what’s paying the bills every week.
Unidentified Analyst: Let’s see what the accountant says at year-end.
Ted Karkus : All right, thank you. All right. I think that was — boy that killed my [Indiscernible]. Nick, if you want to ask if there any more questions, or I’m happy to wrap up.
Operator: On moment, please. [Operator Instructions]
